Rome, Nov 18. (Adnkronos Health) – “In ALS, as in many other neurodegenerative diseases, alterations occur in protein metabolism. These are produced from information contained in RNA. Today we have therapies capable of intervening directly on RNA and, therefore, of modifying the production of abnormal proteins involved in neurodegenerative diseases, starting with ALS. This represents one of the main breakthroughs in research. The results obtained with tofersen in patients with the Sod1 gene mutation and the prospects that are also opening up for the Fus mutation indicate possibilities of great interest. We already know a lot about the mechanisms that regulate protein metabolism in ALS and we have identified some targets to intervene on. Others will be discovered: we are on the right track and I am very optimistic that, by continuing in this direction, new therapeutic solutions can be achieved.” This was stated by Mario Sabatelli, president of the scientific-medical commission of Aisla (Italian Association of Amyotrophic Lateral Sclerosis), speaking at ‘The Promise 2026’, the live marathon organized to support ALS research.
But how can these scientific opportunities be transformed into new, rigorous, and accessible clinical trials also in Italy? “Research is underway concerning the Tardbp gene, a mutation particularly widespread in Italy and France. It is also possible to intervene on this gene through ASOs (antisense oligonucleotides), therapies that act on RNA, but with a particular characteristic: they are personalized and can be developed for individual patients or small groups of people. To understand which of these therapies may be useful for each patient, it is first necessary to prepare the ground. This is precisely the objective of the project: we are collecting and involving people who have a mutation of the Tardbp gene, to subsequently identify who will meet the requirements to participate in a clinical trial or access a therapy,” concluded Sabatelli.